Deglycosylation of VEGF Produced in Pichia pastoris Reduces its in Vitro Binding and Angiogenic Effect
Biotechnology Journal · 2025
DOI: 10.1002/biot.70153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Journal, 2025. Verfasst von Sibel Kalyoncu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Izmir Biomedicine and Genome Center, Izmir, Turkiye. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Saccharomycetales, Pichia. Die Arbeit nennt 54 Literaturangaben.
Abstract (Originalsprache)
Vascular endothelial growth factor (VEGF) is a key pro‐angiogenic glycoprotein used in both research and therapeutic applications. While Pichia pastoris ( Komagataella phaffii ) provides a cost‐effective expression system for recombinant VEGF, its glycosylation patterns differ significantly from those in mammalian systems, and the impact of these modifications remains underexplored. Recombinant human VEGF165 was expressed in P. pastoris , purified via heparin affinity chromatography, and enzymatically deglycosylated using Endo H. Both glycosylated (yVEGF g ) and deglycosylated (yVEGF dg ) forms were characterized for their binding to an anti‐VEGF antibody, bevacizumab, via ELISA and SPR and evaluated for biological activity using HUVEC proliferation assays. Comparative analyses were also conducted with mammalian‐expressed VEGF. Deglycosylated VEGF exhibited reduced binding affinity to bevacizumab and a lower proliferative effect on endothelial cells compared to its glycosylated counterpart. Despite the N‐glycosylation site being structurally distant from receptor/antibody epitopes, glycosylation enhanced VEGF's in vitro binding kinetics and angiogenic activity. Partially glycosylated VEGF from P. pastoris even surpassed mammalian‐expressed VEGF in inducing endothelial proliferation. These findings demonstrate that glycosylation significantly enhances the functional properties of recombinant VEGF produced in P. pastoris , emphasizing the importance of glycosylation control for the development of bioactive VEGF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Izmir Biomedicine and Genome Center, Izmir, Turkiye.
- Dokuz Eylul University, Izmir International Biomedicine and Genome Institute, Izmir, Turkiye.
- VIB-UGent Center for Medical Biotechnology, Ghent, Belgium.
- Department of Food Engineering, Akdeniz University, Engineering Faculty, Antalya, Turkiye.
ORCID-Profile: Sibel Kalyoncu
Zitieren
APA
Kalyoncu, S., Ozer-Cokgezme, C., Arslan, M., Kurden-Pekmezci, A., Erez, O., Cakan-Akdogan, G., & Inan, M. (2025). Deglycosylation of VEGF Produced in Pichia pastoris Reduces its in Vitro Binding and Angiogenic Effect. Biotechnology Journal. https://doi.org/10.1002/biot.70153
Vancouver
Kalyoncu S, Ozer-Cokgezme C, Arslan M, Kurden-Pekmezci A, Erez O, Cakan-Akdogan G, et al. Deglycosylation of VEGF Produced in Pichia pastoris Reduces its in Vitro Binding and Angiogenic Effect. Biotechnology Journal. 2025. doi:10.1002/biot.70153
BibTeX
@article{Kalyoncu2025,
author = {Kalyoncu, Sibel and Ozer-Cokgezme, Ceren and Arslan, Merve and Kurden-Pekmezci, Aslı and Erez, Ozlem and Cakan-Akdogan, Gulcin and Inan, Mehmet},
title = {Deglycosylation of VEGF Produced in Pichia pastoris Reduces its in Vitro Binding and Angiogenic Effect},
journal = {Biotechnology Journal},
year = {2025},
doi = {10.1002/biot.70153}
}
EUVIMED